Adjuvant Therapy in Renal Cell Carcinoma: Current Status and Future Directions

被引:1
|
作者
Kazarian, Austin G. [1 ]
Chawla, Neal S. [2 ]
Muddasani, Ramya [2 ]
Pal, Sumanta K. [2 ]
机构
[1] Univ Iowa, Carver Coll Med, Iowa City, IA USA
[2] City Hope Comprehens Canc Ctr, Dept Med Oncol & Expt Therapeut, 1500 East Duarte Rd, Duarte, CA 91010 USA
关键词
Renal cell carcinoma; adjuvant chemotherapy; cytokines; molecular targeted therapy; precision medicine; BLIND PHASE-III; HIGH-RISK; RADICAL NEPHRECTOMY; INTERFERON-ALPHA; TRIAL; INTERLEUKIN-2; STAGE; RECURRENCE; SURVIVAL; IMMUNOTHERAPY;
D O I
10.3233/KCA-200105
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In recent years, incredible progress has been made in the treatment of metastatic renal cell carcinoma, with a paradigm shift from the use of cytokines to tyrosine kinase inhibitors, and more recently, immune checkpoint inhibitors (ICIs). Despite advances in the metastatic setting, effective therapies in the adjuvant setting are a largely unmet need. Currently, sunitinib (Sutent, Pfizer) is the only therapy for the adjuvant treatment of RCC included in the National Comprehensive Cancer Network guidelines, which was approved by the FDA based on the improvement in disease-free survival (DFS) seen in the S-TRAC trial. However, improvement in DFS has not translated into an overall survival (OS) benefit for patients at high-risk of relapse post-nephrectomy, illustrating the need for more effective therapies. This manuscript will highlight attributes of both historical and current drug trials and their implications on the landscape of adjuvant therapy. Additionally, we will outline strategies for selecting patients in whom treatment would be most beneficial, as optimal patient selection is a crucial step towards improving outcomes in the adjuvant setting. This is especially critical, given the financial cost and pharmacological toxicity of therapeutic agents. Furthermore, we will review the design of clinical trials including the value of utilizing OS as an endpoint over DFS. Finally, we will discuss how the incorporation of genomic data into predictive models, the use of more sensitive imaging modalities for more accurate staging, and more extensive surgical intervention involving lymph node dissection, may impact outcomes.
引用
收藏
页码:9 / 20
页数:12
相关论文
共 50 条
  • [31] Extracranial oligometastatic renal cell carcinoma: current management and future directions
    Loh, Jasmin
    Davis, Ian D.
    Martin, Jarad M.
    Siva, Shankar
    FUTURE ONCOLOGY, 2014, 10 (05) : 761 - 774
  • [32] Current Management Strategy for Metastatic Renal Cell Carcinoma and Future Directions
    Merza, Hussein
    Bilusic, Marijo
    CURRENT ONCOLOGY REPORTS, 2017, 19 (04)
  • [33] De-escalation of Adjuvant Therapy in Operatively Managed HPV Associated Oropharyngeal Carcinoma: Current Status and Future Directions
    Ma, Daniel
    Routman, David M.
    SEMINARS IN RADIATION ONCOLOGY, 2025, 35 (02) : 166 - 172
  • [34] Adjuvant therapy for gastric cancer: Current and future directions
    Foo, Marcus
    Leong, Trevor
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (38) : 13718 - 13727
  • [35] Adjuvant therapy for gastric cancer:Current and future directions
    Marcus Foo
    Trevor Leong
    World Journal of Gastroenterology, 2014, (38) : 13718 - 13727
  • [36] Adjuvant Therapy in Adrenocortical Carcinoma: Reflections and Future Directions
    Bedrose, Sara
    Daher, Marilyne
    Altameemi, Lina
    Habra, Mouhammed Amir
    CANCERS, 2020, 12 (02)
  • [37] NUTRITIONAL THERAPY OF RENAL-FAILURE - CURRENT STATUS, FUTURE-DIRECTIONS
    WALSER, M
    POSTGRADUATE MEDICINE, 1982, 71 (02) : 9 - &
  • [38] Current Status and Future Directions of Gene and Cell Therapy for Cystic Fibrosis
    Uta Griesenbach
    Eric W. F. W. Alton
    BioDrugs, 2011, 25 : 77 - 88
  • [39] Stem Cell Therapy for Tendon Regeneration: Current Status and Future Directions
    Conrad, Sabine
    Weber, Kathrin
    Walliser, Ulrich
    Geburek, Florian
    Skutella, Thomas
    TISSUE ENGINEERING AND REGENERATIVE MEDICINE, 2019, 1084 : 61 - 93
  • [40] Current Status and Future Directions of Gene and Cell Therapy for Cystic Fibrosis
    Griesenbach, Uta
    Alton, Eric W. F. W.
    BIODRUGS, 2011, 25 (02) : 77 - 88